Iceland's Actavis has upped its bid to acquire Croatia's Pliva to $139 a share, surpassing the latest offer from Barr. But analysts say the bidding war isn't over yet. They're waiting to see how Barr reacts to this latest bid and many expect yet another higher bid to hit the table. The winner in the bidding war for Pliva will create the world's third largest generic drug maker, behind Teva and Novartis.
- see the AFX report on Actavis' bid